Effect of thymopentin combined with conventional therapy on serum IL-17A, CXCL12 levels and TRPC1 expression in elderly patients with chronic obstructive pulmonary disease

Objective To investigate the effect of thymopentin combined with routine medication on serum interleukin 17A(IL-17A), chemokine 12(CXCL12) levels and transient receptor potential channel 1(TRPC1) expression in elderly patients with chronic obstructive pulmonary disease (COPD). Methods 156 COPD patients were selected as study objects.They were randomly divided into two groups(n=78) according to the digital table.The control group received routine treatment, and the observation group received subcutaneous injection of thymopentin on the basis of routine treatment.Before and after treatment, the CD3+ , CD4+ , CD8+ , CD4+ /CD8+ levels were tested to compare the immunologic function of the two groups.Before and after treatment, the FEV1, FEV1/FVC, PEF were tested to compare the pulmonary ventilation function of the two groups.The IL-17A, CXCL12 levels in peripheral blood and TRPC1 level in bronchoalveolar liquid before and after treatment were tested and compared between the two groups.The adverse effect was compared. Results Before treatment, the CD3+ , CD4+ , CD8+ and CD4+ /CD8+ between the two groups had not statistically significant differences(all P>0.05), which of the control group after treatment had no significant change (all P>0.05), the CD3+ , CD4+ , CD4+ /CD8+ of the observation group[(65.17±2.39)%, (41.06±2.15)%, (1.50±0.74)%] were significantly higher than control group[(52.66±2.38)%, (32.30±2.05)%, (0.80±0.81)%](all P 0.05). After treatment, the peripheral blood IL-17A[(24.18±3.69)pg/mL], CXCL12 levels[(193.50±2.90)pg/mL]and TRPC1 level in BALF[(7.69±1.14)ng/L]in the observation group decreased significantly(P 0.05). Conclusion Thymopentin combined with conventional therapy can effectively improve the elderly COPD patients' immunologic function and pulmonary ventilation function, decrease the inflammatory factor, relieve inflammatory reaction and it is safe and effective. Key words: Pulmonary disease, chronic obstructive; Interleukin-17A; Chemokine 12; Transient receptor potential channel 1; Thymopoietin5